VIR Q3 2023 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-99.3% YoY

Gross Profit

-$142M-5397.0% margin

Operating Income

-$187M-7075.9% margin

Net Income

-$163M-6192.2% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

-30.5%

Cash Flow

Operating Cash Flow

-$156M

Free Cash Flow

-$160M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$370M

Stockholders' Equity

$1.7B

Cash & Equivalents

$452M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$375M	-99.3%
Gross Profit	-$142M	$238M	-159.8%
Operating Income	-$187M	$195M	-195.8%
Net Income	-$163M	$175M	-193.2%

Revenue Segments

Grant

$7M96%

Contract Revenue

$289,0004%